Edwards Cardioband Mitral Reconstruction System

A New Era for Transcatheter Mitral Repair

European CE mark trial – two-year results

Single-arm, multicentre prospective study designed to evaluate the performance and safety of the Cardioband mitral system for treatment of functional mitral regurgitation.

96% of patients with MR≤2+ at 2 years by core lab* in paired analysis[1]



29% average annular reduction by core lab[1]*



Edwards Cardioband Mitral Reconstruction System

Functional improvement at 2 years[1]

NYHA Class



MLHFQ Score



6MWT



NYHA – New York Heart Association, Functional Classification
MLHFQ – Minnesota Living with Heart Failure Questionnaire
6MWT – Six-Minute Walk Test

For more information, please visit **www.edwards.com/CardiobandMR**

References

1. F. Maisano, M.D. Transcatheter mitral valve repair in patients with functional mitral regurgitation: 2 year follow-up of the multicenter CE trial, presented at PCR London Valves 2018.

* Dr. Paul Grayburn – Baylor University.

** t-test

† ANOVA t-test

†† McNemar's test

For professional use. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

Edwards Lifesciences devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity. Cardioband Systems are manufactured by Valtech Cardio Ltd. for Edwards Lifesciences.

Edwards Lifesciences • Route de l'Etraz 70, 1260 Nyon, Switzerland • edwards.com

Edwards